Considering the diverse benefits of GLP-1 on hyperglycemia, food intake, and even β cell function, Rg3 has possibility to be developed as a novel therapeutic agent for type 2 diabetes and obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.